Renvela
Generic name: Sevelamer
Drug class:
Phosphate binders
Usage of Renvela
Renvela is a phosphate binder. Sevelamer helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus.
Renvela is used to control phosphorus levels in people with chronic kidney disease who are on dialysis.
Renvela may also be used for purposes not listed in this medication guide.
Renvela side effects
Get emergency medical help if you have signs of an allergic reaction to Renvela: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using Renvela and call your doctor at once if you have:
Common Renvela side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Renvela
You should not take Renvela if you are allergic to sevelamer, or if you have a bowel obstruction.
To make sure Renvela is safe for you, tell your doctor if you have:
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. Your dose needs may be different during pregnancy.
Taking Renvela while you are pregnant can lower your blood levels of certain vitamins or folic acid. Follow your doctor's instructions about taking vitamins or mineral supplements during pregnancy.
Because sevelamer is not absorbed into the bloodstream, it is not expected to be harmful to a nursing baby.
Renvela is not approved for use by anyone younger than 6 years old.
Relate drugs
- Auryxia
- Ferric citrate
- Fosrenol
- Lanthanum carbonate
- Renagel
- Renvela
- Sevelamer
- Sucroferric oxyhydroxide
- Velphoro
How to use Renvela
Usual Adult Dose for Hyperphosphatemia of Renal Failure:
Initial Dosing for patients not on a phosphate binder: 800 mg to 1600 mg orally 3 times a day with meals. Based on serum phosphorus level: -Phosphorus greater than 5.5 to less than 7.5 mg/dL: 800 mg 3 times a day with meals -Phosphorus greater than or equal to 7.5 to less than 9 mg/dL: 1200 to 1600 mg 3 times a day with meals -Phosphorus greater than or equal to 9 mg/dL: 1600 mg 3 times a day with meals -Titrate in increments of 800 mg 3 times a day at 2-week intervals with the goal of controlling serum phosphorus within target range. Average prescribed dose: 7.2 g/day (2.4 g with each meal) Maximum studied dose: 14 g per day (carbonate); 13 g per day (hydrochloride) Switching from the hydrochloride salt to carbonate: Use the same dose, however further titration may be necessary to achieve desired phosphorus levels. Switching from Calcium acetate: Substitute approximately mg for mg Comment: Treatment of hyperphosphatemia includes reduction in dietary intake of phosphate, inhibition of intestinal phosphate absorption with phosphate binders, and removal of phosphate with dialysis. Use: To control serum phosphorus levels in patients with chronic kidney disease on dialysis.
Warnings
You should not take Renvela if you have a bowel obstruction.
Before taking Renvela, tell your doctor if you have severe constipation, a blockage in your intestines, a stomach or intestinal disorder, trouble swallowing, or if you have recently had stomach or intestinal surgery.
Avoid taking any other medicines within 1 hour before or 3 hours after you take Renvela. Sevelamer can bind to other medications and make them less effective.
Before taking this medicine, tell your doctor if you are taking ciprofloxacin (Cipro), a heart rhythm medication, or a seizure medication.
Do not take calcium or other mineral supplements without your doctor's advice. Use only the specific type of calcium or mineral supplement your doctor recommends.
What other drugs will affect Renvela
Other drugs may interact with Renvela, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions